Seres Therapeutics to Showcase CARB-X-Backed AMR Efforts at Investor Day
Event summary
- Seres Therapeutics will present at the 2026 CARB-X Investor Day on April 16, 2026.
- The company received a $3.6M non-dilutive award from CARB-X in 2025 for SER-428 development.
- SER-428 is an oral liquid formulation for ICU patients at high risk of AMR infections.
- Seres is designing a Phase 1b trial for SER-428 in collaboration with Columbia University.
The big picture
Seres Therapeutics' presentation at the CARB-X Investor Day highlights its strategic focus on combating antimicrobial resistance, a critical global health threat. The company's collaboration with CARB-X and its development of SER-428 underscore its commitment to addressing unmet medical needs in vulnerable patient populations. The event provides a platform for Seres to showcase its innovative therapeutics and attract potential collaborators and investors.
What we're watching
- Clinical Progress
- The pace at which Seres advances SER-428 into Phase 1b trials will indicate its ability to address unmet needs in ICU patients.
- Funding Dynamics
- Whether CARB-X's continued support can sustain Seres' pipeline development amid financial constraints.
- Market Positioning
- How Seres differentiates itself in the competitive landscape of live biotherapeutics for inflammatory and immune diseases.
Our editorial coverage:
Related topics